

MACULAR DEGENERATION AGENTS PRIOR AUTHORIZATION FORM

Prior authorization guidelines for Macular Degeneration Agents and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

New request	Total # pages:	Prescriber name:		
Name of office contact:		Specialty:		
Contact's phone number:		State license #:		NPI:
LTC facility contact/phone:		Street address:		
Beneficiary name:		Suite #:	City/state/zip:	
Beneficiary ID#:	DOB:	Phone:		Fax:
CLINICAL INFORMATION				
Drug requested:		Strength: Formulation (syringe, v		Formulation (syringe, vial, etc.):
Directions (dose, eye[s] to be treated, frequency, etc.):				Requested duration:
Diagnosis:				Dx code (required):
INITIAL requests				
Has the beneficiary tried and failed or have a contraindication or an intolerance to intravitreal bevacizumab ?			□Yes – Submit all supporting documentation of bevacizumab regimen and treatment outcome. □No □Not clinically appropriate	
For a non-preferred medication: Does the beneficiary have a history of trial and failure of or a contraindication or an intolerance of the preferred agents in this class that are approved or medically accepted for the beneficiary's diagnosis? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.			☐ Yes – Submit documentation. ☐ No ☐ Not applicable to diagnosis	
RENEWAL requests List previous doses of the requested medication:				
Right eye: Left eye:				
Has the beneficiary experienced a positive clinical response to previously administered doses of the requested medication?				Submit medical record documentation of beneficiary's response to treatment.
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS - PHARMACY DIVISION				
Prescriber Signature:				Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.